Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company was founded in 2009 and is based in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: nemauramedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/29/2022 | $12.00 | Buy | H.C. Wainwright |
| 12/2/2021 | $7.50 | Buy | EF Hutton |
4 - Nemaura Medical Inc. (0001602078) (Issuer)